Stage IV Gastric Cancer Clinical Trial
— DREAMOfficial title:
A Randomized, Open, Multicenter Phase 3 Study for Efficacy and Safety Assessment of DHP107 (Oral Paclitaxel) vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy With Fluoropyrimidine +/- Platinum
Verified date | August 2015 |
Source | Daehwa Pharmaceutical Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | Korea: Food and Drug Administration |
Study type | Interventional |
The objective of this study is to evaluate the efficacy and safety of DHP107 (Oral paclitaxel) in comparison to Taxol®(IV paclitaxel) in Patients With Metastatic or Recurrent Gastric Cancer After Failure of 1st Line Chemotherapy With Fluoropyrimidine +/- Platinum.
Status | Completed |
Enrollment | 238 |
Est. completion date | August 2015 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: 1. =20 years of age 2. Histologically or cytologically confirmed unresectable, recurrent or metastatic gastric cancer 3. Failure of a first line therapy with fluoropyrimidine +/- platinum for metastatic or recurrent disease.(Adjuvant chemotherapy is not considered as a first line chemotherapy unless recurrence developed within 6 months of completion of adjuvant therapy.) 4. Adequate bone marrow, liver and renal functions 5. INR = 2.0 6. ECOG performance status = 2 7. Neuropathy grade = 1 8. Life expectancy of at least 3 months 9. Measurable lesion according to RECIST version 1.1 on CT scan 10. Written informed consent 11. Patients of child bearing age have to agree to the usage of adequate contraception from before the registration to the study, during the participation period and 90 days after the end of treatment. Female of child bearing age has to show negative for urin pregnancy test within 7 days from beginning of the start of administration. Amenorrhea status has to be sustained for at least 12 months to be considered non-pregnant in case of postmenstrual women. Exclusion Criteria: 1. Major infectious disease, neurological disorder, or bowel obstruction. 2. Patients with CNS metastases(confirmed through brain imaging if there are symptoms) 3. Patient diagnosed with another cancer type (except non-melanoma skin cancer, cervical cancer, or any other cancer that did not recur or metastasized for more than 5 years and considered as complete remission can be registered) 4. Patient who received radiation therapy within past 2 weeks or who had major surgery including organ resection within past 4 weeks from random assignment date 5. Patient with the history of failure to the taxane chemotherapy 6. Patient who need chronic concomitant use of P glycoprotein, immune suppressor, proton pump inhibitor, or H2-receptor antagonist during the period of clinical trial 7. Chronic treatment using steroid (except oral, local injection, or for externally applied) or other immune suppressor 8. Patient with myocardial infarction, congestive heart failure, arrhythmia showing abrupt change in the ECG, severe or unstable angina, or other serious heart disease 9. Patient with other serious internal disease (chronic obstructive or chronic inhibitory lung disease including shortness of breathe at rest due to all reasons, uncontrollable diabetes and hypertension) 10. History of abuse of a drug or alcohol within 3 months 11. Lactating or pregnant women, or patient (or spouse) who has no intension of using, or cannot use very effective mean of contraception 12. Patient who has or is suspected to have problem in bile acid secretion 13. Patient with active gastrointestinal bleeding, or taking oral anti- vitamine K (With the exception of low dose of Warfarin and acetylsalicylic acide when INR=2.0) 14. History of serious hypersensitive reaction to the main ingredient or the excipient of the investigational drug 15. History of being seropositive for HIV (HIV test is not a prerequisite). 16. Patients with gastrointestinal dysfunction or on enteral feeding 17. Other patients who are deemed inadequate to participate in the clinical trial by the investigator |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Inje University Haeundae Paik Hospital | Busan | |
Korea, Republic of | Kyungpook National University Medical Center | Daegu | |
Korea, Republic of | National Cancer Center | Goyang-si, Gyeonggi-do | |
Korea, Republic of | Chonnam National University Hwasun Hospital | Jeollanam-do | |
Korea, Republic of | Seoul National University Bundang Hospital | Seongnam-si, Gyeonggi-do | |
Korea, Republic of | Asan Medical Center | Seoul | |
Korea, Republic of | Korea University Guro Hospital | Seoul | |
Korea, Republic of | Samsung Medical Center | Seoul | |
Korea, Republic of | Seoul St. Mary's Hospital | Seoul | |
Korea, Republic of | Yonsei University Gangnam Severance Hospital | Seoul | |
Korea, Republic of | Yonsei University Severance Hospital | Seoul | |
Korea, Republic of | Ajou University Hospital | Suwon |
Lead Sponsor | Collaborator |
---|---|
Daehwa Pharmaceutical Co., Ltd. |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression Free Survival (PFS) | Progression Free Survival (PFS) is defined as the time From date of randomization until the date of first documented progression or death, assessed up to 24 months. | Participants will be followed until progression, an expected average of 4 months. | No |
Secondary | Overall Survival (OS) | Overall survival (OS) is defined as the time from the date of inclusion to the date of death, regardless of the cause of death. | Until 6 months after the last participant is enrolled, assessed up to 24 months. | No |
Secondary | Overall Response Rate (ORR) | Overall Response Rate (ORR) is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria. | Participants will be followed every 6 weeks until progression, an expected average of 4 months. | No |
Secondary | Safety | Number and Description of Adverse Events | Up to 24 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02291211 -
S-1 Combined Cisplatin HIPEC for Palliative Operation Gastric Cancer of Stage IV Limited Peritoneal Metastasis
|
Phase 2 | |
Terminated |
NCT01705340 -
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
|
Phase 1 | |
Completed |
NCT01178944 -
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
|
Phase 2 | |
Completed |
NCT00991952 -
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00982592 -
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
|
Phase 2 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01191684 -
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
|
Phase 1 | |
Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00006389 -
Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer
|
Phase 2 | |
Terminated |
NCT01249443 -
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
|
Phase 1 | |
Completed |
NCT01612546 -
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
|
Phase 2 | |
Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
Active, not recruiting |
NCT01939275 -
64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer
|
N/A | |
Active, not recruiting |
NCT01637805 -
Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer
|
Phase 1 | |
Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A | |
Withdrawn |
NCT02344810 -
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01643499 -
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
|
Phase 1 | |
Completed |
NCT00084617 -
Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
|
Phase 2 | |
Completed |
NCT00068380 -
A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer
|
Phase 2 | |
Terminated |
NCT00064259 -
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
|
Phase 1/Phase 2 |